Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)

NCT01350115 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Basal Cell Carcinoma
Gorlin Syndrome
Nevoid Basal Cell Carcinoma Syndrome

Interventions

DRUG: LDE225
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals